Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment

ClinicalTrials.gov ID: NCT01620489

Public ClinicalTrials.gov record NCT01620489. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment. A 26-week Double-blind Placebo-controlled, Randomised, Multicentre, Multi-national, Parallel-group Trial

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of liraglutide in subjects with type 2 diabetes and moderate renal impairment. The trial medication will be add-on to the subject's stable pre-trial OAD and/or insulin regimen.

Study identification

NCT ID
NCT01620489
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
279 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 13, 2012
Primary completion
Aug 19, 2013
Completion
Aug 19, 2013
Last update posted
Mar 18, 2019

2012 – 2013

United States locations

U.S. sites
53
U.S. states
21
U.S. cities
50
Facility City State ZIP Site status
Novo Nordisk Investigational Site Concord California 94520
Novo Nordisk Investigational Site La Jolla California 92037
Novo Nordisk Investigational Site Los Angeles California 90057
Novo Nordisk Investigational Site Monterey California 93940
Novo Nordisk Investigational Site San Diego California 92111
Novo Nordisk Investigational Site San Ramon California 94583
Novo Nordisk Investigational Site Torrance California 90502
Novo Nordisk Investigational Site Tustin California 92780
Novo Nordisk Investigational Site Ventura California 93003
Novo Nordisk Investigational Site Golden Colorado 80401
Novo Nordisk Investigational Site Boynton Beach Florida 33472
Novo Nordisk Investigational Site Jacksonville Florida 32216
Novo Nordisk Investigational Site Miami Florida 33156
Novo Nordisk Investigational Site Pembroke Pines Florida 33027
Novo Nordisk Investigational Site Plantation Florida 33324
Novo Nordisk Investigational Site St. Petersburg Florida 33711
Novo Nordisk Investigational Site Atlanta Georgia 30303
Novo Nordisk Investigational Site Roswell Georgia 30076
Novo Nordisk Investigational Site Avon Indiana 46123
Novo Nordisk Investigational Site Franklin Indiana 46131
Novo Nordisk Investigational Site Greenfield Indiana 46140
Novo Nordisk Investigational Site Muncie Indiana 47304
Novo Nordisk Investigational Site Slidell Louisiana 70461-4231
Novo Nordisk Investigational Site Rockville Maryland 20852
Novo Nordisk Investigational Site Springfield Massachusetts 01199
Novo Nordisk Investigational Site Buckley Michigan 49620
Novo Nordisk Investigational Site Southfield Michigan 48034-7661
Novo Nordisk Investigational Site Great Falls Montana 59405
Novo Nordisk Investigational Site Nashua New Hampshire 03063
Novo Nordisk Investigational Site Rosedale New York 11422
Novo Nordisk Investigational Site Staten Island New York 10301
Novo Nordisk Investigational Site Greenville North Carolina 27834
Novo Nordisk Investigational Site Mooresville North Carolina 28117
Novo Nordisk Investigational Site Franklin Ohio 45005
Novo Nordisk Investigational Site Mason Ohio 45040-6815
Novo Nordisk Investigational Site Wadsworth Ohio 44281-9236
Novo Nordisk Investigational Site Oklahoma City Oklahoma 73104
Novo Nordisk Investigational Site McMurray Pennsylvania 15317
Novo Nordisk Investigational Site Norristown Pennsylvania 19401
Novo Nordisk Investigational Site Philadelphia Pennsylvania 19107
Novo Nordisk Investigational Site East Providence Rhode Island 02914
Novo Nordisk Investigational Site Chattanooga Tennessee 37404-1192
Novo Nordisk Investigational Site Chattanooga Tennessee 37411
Novo Nordisk Investigational Site Kingsport Tennessee 37660
Novo Nordisk Investigational Site Amarillo Texas 79106
Novo Nordisk Investigational Site Lubbock Texas 79423
Novo Nordisk Investigational Site Sugar Land Texas 77479
Novo Nordisk Investigational Site Newport News Virginia 23606
Novo Nordisk Investigational Site Richmond Virginia 23219
Novo Nordisk Investigational Site Richmond Virginia 23294
Novo Nordisk Investigational Site Richmond Virginia 23298
Novo Nordisk Investigational Site Winchester Virginia 22601
Novo Nordisk Investigational Site Milwaukee Wisconsin 53209

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 44 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01620489, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 18, 2019 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01620489 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →